<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03546608</url>
  </required_header>
  <id_info>
    <org_study_id>MS200095_0028</org_study_id>
    <nct_id>NCT03546608</nct_id>
  </id_info>
  <brief_title>Tepotinib Hepatic Impairment Trial</brief_title>
  <official_title>Open-Label, Parallel-Group Phase 1 Study to Investigate the Effect of Various Degrees of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of the c-Met Kinase Inhibitor Tepotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the effect of various degrees of hepatic impairment on the
      pharmacokinetics (PK), safety and tolerability of tepotinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Actual">February 5, 2019</completion_date>
  <primary_completion_date type="Actual">February 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC 0-t) of Tepotinib</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Tepotinib</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Tepotinib</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (tmax) of Tepotinib</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-Life (t1/2) of Tepotinib</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance of Tepotinib From Plasma Following Oral Administration (CL/f)</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution of Tepotinib During the Terminal Phase Following Extravascular Administration (VZ/f)</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve Extrapolated From Time t to Infinity as a Percentage of AUC 0-inf (AUC extra%) of Tepotinib</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC 0-t) of Tepotinib Metabolites MSC2571109 and MSC2571107</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Tepotinib Metabolites MSC2571109 and MSC2571107</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Tepotinib Metabolites MSC2571109 and MSC2571107</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (tmax) of Tepotinib Metabolites MSC2571109 and MSC2571107</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-Life (t1/2) of Tepotinib Metabolites MSC2571109 and MSC2571107</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve Extrapolated From Time t to Infinity as a Percentage of AUC 0-inf (AUC extra%) of Tepotinib Metabolites MSC2571109 and MSC2571107</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tepotinib Metabolites (MSC2571109 or MSC2571107) AUC 0-inf to tepotinib AUC 0-inf ratio (MRAUC0-inf)</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tepotinib Metabolites (MSC2571109 or MSC2571107) Cmax to tepotinib Cmax ratio (MRCmax)</measure>
    <time_frame>Pre-dose up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Day 1 up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinically Significant Abnormalities in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Day 1 up to Day 22</time_frame>
    <description>Number of subjects with clinically significant abnormalities will be reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Part 1, Child-Pugh Class A: Tepotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Child-Pugh Class B: Tepotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Healthy Participants: Tepotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants matched to Child-Pugh Class B participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tepotinib</intervention_name>
    <description>Participants will receive a single oral dose of tepotinib in Part 1.</description>
    <arm_group_label>Part 1, Child-Pugh Class A: Tepotinib</arm_group_label>
    <arm_group_label>Part 1, Child-Pugh Class B: Tepotinib</arm_group_label>
    <arm_group_label>Part 1, Healthy Participants: Tepotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women (of nonchildbearing potential), with a body mass index of 18 to 36
             kilograms per meter square (inclusive) and a body weight greater than or equal to 50
             kilograms at screening, with the absence of acute hepatitis or Human Immunodeficiency
             Virus 1 and 2, who have given informed consent and are willing and able to comply with
             study procedures will be eligible for enrollment

          -  Participants with impaired hepatic function (Child-Pugh class A or Child-Pugh class B)
             and participants with normal hepatic function will be eligible to enroll in the study

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Healthy participants will be excluded if they have hepatitis B or C or had a previous
             infection with hepatitis C treated with Sofosbuvir or other antiviral compounds, or
             any other clinically relevant disease, as considered by the Investigator

          -  Participants with impaired hepatic function will be excluded if they have primary
             biliary liver cirrhosis, nonstabilized chronic heart failure, hepatocarcinoma, hepatic
             encephalopathy (Grade III or IV), sepsis or gastrointestinal bleeding, or any other
             clinically relevant disease, as considered by the Investigator

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Research &amp; Development Institute, Inc., the biopharmaceutical division of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qps Mra, Llc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Tepotinib</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

